Does the media prefer ABVX or VRDN?

In the previous week, Viridian Therapeutics had 5 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Viridian Therapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.49 beat Viridian Therapeutics' score of 1.23 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or PRAX?

In the previous week, Viridian Therapeutics had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Viridian Therapeutics and 5 mentions for Praxis Precision Medicines. Viridian Therapeutics' average media sentiment score of 1.23 beat Praxis Precision Medicines' score of 1.10 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Kymera Therapeutics' score of 0.94 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IONS or VRDN?

In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than Viridian Therapeutics. MarketBeat recorded 39 mentions for Ionis Pharmaceuticals and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Ionis Pharmaceuticals' score of 0.35 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 10 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral Viridian Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or VRDN?

In the previous week, Viridian Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Viridian Therapeutics and 5 mentions for Protagonist Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Protagonist Therapeutics' score of 0.81 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$22.73 -0.44 (-1.90%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$22.74 +0.01 (+0.04%)

As of 09/9/2026 07:30 PM Eastern

Compare

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

Should you buy Viridian Therapeutics stock or one of its competitors? Viridian Therapeutics's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Viridian Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

47.9% of Abivax shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Viridian Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Viridian Therapeutics	$70.85M	36.35	-$342.60M	-$3.37	N/A

Abivax currently has a consensus price target of $156.38, suggesting a potential upside of 30.91%. Viridian Therapeutics has a consensus price target of $38.54, suggesting a potential upside of 69.55%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Abivax has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, Viridian Therapeutics had 5 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Viridian Therapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.49 beat Viridian Therapeutics' score of 1.23 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viridian Therapeutics beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Viridian Therapeutics (NASDAQ:VRDN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Praxis Precision Medicines has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Praxis Precision Medicines' return on equity of -34.15% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

In the previous week, Viridian Therapeutics had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Viridian Therapeutics and 5 mentions for Praxis Precision Medicines. Viridian Therapeutics' average media sentiment score of 1.23 beat Praxis Precision Medicines' score of 1.10 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viridian Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

Viridian Therapeutics presently has a consensus price target of $38.54, indicating a potential upside of 69.55%. Praxis Precision Medicines has a consensus price target of $585.95, indicating a potential upside of 69.69%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Praxis Precision Medicines has lower revenue, but higher earnings than Viridian Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	36.35	-$342.60M	-$3.37	N/A
Praxis Precision Medicines	$8.55M	1,127.58	-$303.27M	-$12.93	N/A

Summary

Praxis Precision Medicines beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Viridian Therapeutics compare to Kymera Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Viridian Therapeutics' net margin of -505.86%. Kymera Therapeutics' return on equity of -21.22% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

In the previous week, Kymera Therapeutics had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Kymera Therapeutics' score of 0.94 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	36.35	-$342.60M	-$3.37	N/A
Kymera Therapeutics	$39.21M	244.78	-$311.35M	-$3.24	N/A

Viridian Therapeutics currently has a consensus target price of $38.54, indicating a potential upside of 69.55%. Kymera Therapeutics has a consensus target price of $128.70, indicating a potential upside of 11.49%. Given Viridian Therapeutics' higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kymera Therapeutics beats Viridian Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Viridian Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$874.09M	10.65	-$381.39M	-$3.46	N/A
Viridian Therapeutics	$70.85M	36.35	-$342.60M	-$3.37	N/A

Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus price target of $91.25, suggesting a potential upside of 62.89%. Viridian Therapeutics has a consensus price target of $38.54, suggesting a potential upside of 69.55%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a net margin of -64.76% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than Viridian Therapeutics. MarketBeat recorded 39 mentions for Ionis Pharmaceuticals and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Ionis Pharmaceuticals' score of 0.35 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	10 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral
Viridian Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viridian Therapeutics beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Protagonist Therapeutics currently has a consensus target price of $147.13, suggesting a potential upside of 1.41%. Viridian Therapeutics has a consensus target price of $38.54, suggesting a potential upside of 69.55%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Protagonist Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	204.02	-$130.15M	$1.03	140.86
Viridian Therapeutics	$70.85M	36.35	-$342.60M	-$3.37	N/A

In the previous week, Viridian Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Viridian Therapeutics and 5 mentions for Protagonist Therapeutics. Viridian Therapeutics' average media sentiment score of 1.23 beat Protagonist Therapeutics' score of 0.81 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a net margin of 29.40% compared to Viridian Therapeutics' net margin of -505.86%. Protagonist Therapeutics' return on equity of 12.03% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Protagonist Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats Viridian Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.62B	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.62%	2.55%	9.95%
P/E Ratio	-6.74	12.94	271.79	25.29
Price / Sales	36.35	1,459.61	709.75	113.08
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	3.68	15.81	10.63	6.26
Net Income	-$342.60M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-1.00%	-0.13%	-1.19%	-0.56%
1 Month Performance	-1.43%	4.54%	1.99%	-1.04%
1 Year Performance	14.68%	46.20%	21.89%	11.31%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.5454 of 5 stars	$22.73 -1.9%	$38.54 +69.5%	+12.5%	$2.62B	$70.85M	N/A	50	Positive News
ABVX Abivax	2.5196 of 5 stars	$114.79 flat	$156.50 +36.3%	+33.8%	$10.02B	N/A	N/A	61	Positive News Analyst Forecast
PRAX Praxis Precision Medicines	3.1614 of 5 stars	$351.81 flat	$585.95 +66.6%	+762.6%	$9.82B	$8.55M	N/A	110	Positive News
KYMR Kymera Therapeutics	1.7022 of 5 stars	$117.39 flat	$128.70 +9.6%	+165.5%	$9.76B	$39.21M	N/A	170
IONS Ionis Pharmaceuticals	3.3994 of 5 stars	$58.09 flat	$92.95 +60.0%	-13.0%	$9.65B	$944M	N/A	1,402	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Viridian Therapeutics compare to Abivax?

Summary

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Summary

How does Viridian Therapeutics compare to Kymera Therapeutics?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Viridian Therapeutics compare to Abivax?

Do institutionals and insiders have more ownership in ABVX or VRDN?

Which has stronger earnings and valuation, ABVX or VRDN?

Do analysts rate ABVX or VRDN?

Is ABVX or VRDN more profitable?

Which has more risk and volatility, ABVX or VRDN?

Does the media prefer ABVX or VRDN?

Summary

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Is VRDN or PRAX more profitable?

Does the media refer more to VRDN or PRAX?

Which has more volatility & risk, VRDN or PRAX?

Do analysts prefer VRDN or PRAX?

Do institutionals & insiders believe in VRDN or PRAX?

Which has preferable earnings & valuation, VRDN or PRAX?

Summary

How does Viridian Therapeutics compare to Kymera Therapeutics?

Which has more risk & volatility, VRDN or KYMR?

Is VRDN or KYMR more profitable?

Does the media prefer VRDN or KYMR?

Which has stronger valuation & earnings, VRDN or KYMR?

Do analysts prefer VRDN or KYMR?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Which has higher valuation and earnings, IONS or VRDN?

Which has more volatility and risk, IONS or VRDN?

Do analysts recommend IONS or VRDN?

Do insiders and institutionals hold more shares of IONS or VRDN?

Is IONS or VRDN more profitable?

Does the media prefer IONS or VRDN?

Summary

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Do analysts recommend PTGX or VRDN?

Which has stronger earnings & valuation, PTGX or VRDN?

Does the media prefer PTGX or VRDN?

Is PTGX or VRDN more profitable?

Which has more risk & volatility, PTGX or VRDN?

Do insiders & institutionals hold more shares of PTGX or VRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools